Letter to the Editor
Efficacy of Vedolizumab for Inflammatory Bowel Disease in the Setting of DiGeorge Syndrome
Eve Thau,
Eve Thau
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author Hillary Aaron Moore,
Hillary Aaron Moore
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author Philip Stein,
Philip Stein
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author Kathy Chen,
Kathy Chen
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author
Eve Thau,
Eve Thau
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author Hillary Aaron Moore,
Hillary Aaron Moore
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author Philip Stein,
Philip Stein
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author Kathy Chen,
Kathy Chen
Section of Gastroenterology, Hepatology and Nutrition, St. Christopher's Hospital for Children, Department of Pediatrics, Drexel University College of Medicine, Philadelphia, PA
Search for more papers by this author
First published: 01 May 2019
No abstract is available for this article.
REFERENCES
- 1.Uy R, Jacobs N, Mziray-Andrew C. Inflammatory bowel disease and diverticulosis in an adolescent with DiGeorge syndrome. J Pediatr Gastroenterol Nutr 2016; 62: e43–e45.
- 2.Jawad A, McDonald DM, Zackai E, et al. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 2001; 139: 715–723.
- 3.Conrad MA, Stein R, Maxwell EC, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. J Inflamm Bowel Dis 2016; 22: 2425–2431.
- 4.Feagan B, Rutgeerts P, Sands B, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New Engl J Med 2013; 369: 699–710.
- 5.Sandborn W, Feagan B, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New Engl J Med 2013; 369: 711–721.
- 6.Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. J Inflamm Bowel Dis 2016; 22: 2121–2126.
